Bhushan Shriya, McLeod Howard, Walko Christine M
School of Pharmacy, University of North Carolina, Chapel Hill 27599-7360, USA.
Clin Colorectal Cancer. 2009 Jan;8(1):15-21. doi: 10.3816/CCC.2009.n.003.
Predicting response and limiting drug-induced toxicity are 2 important challenges faced by clinicians in the treatment of colorectal cancer (CRC). The introduction of genetic testing to individualize treatment regimens will hopefully allow better response prediction and limit drug-induced toxicity leading to improved patient outcomes. This review discusses the role of the predictive genetic tests associated with the major therapeutic agents used in the treatment of CRC and their clinical significance in the determination of patient-specific treatment regimens.
预测反应和限制药物诱导的毒性是临床医生在治疗结直肠癌（CRC）时面临的两个重要挑战。引入基因检测以实现治疗方案个体化有望实现更好的反应预测，并限制药物诱导的毒性，从而改善患者预后。本综述讨论了与CRC治疗中使用的主要治疗药物相关的预测性基因检测的作用及其在确定患者特异性治疗方案中的临床意义。
